EGFR and neoplasm: To determine the impact of EZN4150-mediated p110α ablation on HER2+ tumor cell response to the EGFR/HER2 tyrosine kinase inhibitor (TKI) lapatinib [28], we treated SKBR3, BT474, and UACC893 cells with EZN4150 in the presence or absence of lapatinib.